Key result
Dara-CyBorD yields limited cardiac response and dialysis dependence in advanced multi-organ AL amyloidosis.
Why the study?
Post-partial nephrectomy, mild proteinuria may occur, but progressive glomerular disease such as AL amyloidosis years later is rare.
Case Report (n=1)
AL amyloidosis can occur in patients with a remote history of renal cell carcinoma, and early recognition is critical as advanced multi-organ involvement may limit recovery despite appropriate chemotherapy.
May limit recovery in advanced multi-organ AL amyloidosis despite Dara-CyBorD; leaves open optimal intervention timing in RCC survivors.
Background: Primary AL amyloidosis is a rare systemic disorder caused by deposition of misfolded immunoglobulin light chains, leading to multi-organ dysfunction. Renal cell carcinoma (RCC) is common, with an age-adjusted incidence of 16.4 per 100,000 persons per year in the US (2017–2021). Post-partial nephrectomy, mild proteinuria may occur, but progressive glomerular disease such as AL amyloidosis years later is rare. Case Presentation: A 73-year-old man with ulcerative colitis, type 2 diabetes, RCC post right partial nephrectomy (10 years prior), and prostate cancer post-prostatectomy (4 years prior) presented with fatigue and bilateral leg edema. Laboratory evaluation revealed acute kidney injury with nephrotic-range proteinuria, hypoalbuminemia, and elevated cardiac biomarkers. Serum and urine protein electrophoresis revealed IgA kappa monoclonal protein. Renal biopsy confirmed AL amyloidosis, and endomyocardial biopsy confirmed cardiac involvement. Bone marrow biopsy showed 10% clonal plasma cells without myeloma-defining events, excluding multiple myeloma. The patient received Dara-CyBorD chemotherapy and hemodialysis. Despite therapy, renal function remained dialysis-dependent, and cardiac and hematologic responses plateaued after one year. Discussion: This case highlights the diagnostic challenges and multi-organ involvement of AL amyloidosis in a patient with prior malignancy. RCC and AL amyloidosis coexist independently, and early recognition is critical for management. Conclusion: AL amyloidosis can occur in patients with a remote history of RCC. Clinicians should maintain high suspicion in patients with nephrotic-range proteinuria and cardiac involvement. Early recognition, staging, and therapy may improve outcomes, although irreversible organ damage may limit recovery.
No takes yet. Share an insight, caveat, or question.
Bector et al. (2026) conducted a case report in Primary AL amyloidosis (n=1). Dara-CyBorD chemotherapy and hemodialysis was evaluated on Clinical response (renal, cardiac, hematologic). In a 73-year-old man with a remote history of renal cell carcinoma, treatment with Dara-CyBorD for primary AL amyloidosis resulted in plateaued cardiac and hematologic responses and dialysis-dependent renal function due to advanced multi-organ involvement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: